Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPM2A | O95278 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.34 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605170 | 0.75 | EPM2A (0.53) | EPM2APTPRCPTPN6CDC14APTPN22 | |
| Benzene SCHEMBL29028842 | 0.72 | EPM2A (0.50) | EPM2APTPRCPTPN6CDC14APTPN22 | |
| SCHEMBL25814574 | 0.71 | CYP19A1 (0.42) | ALDH1A1CYP19A1NPC1RAB9ALTB4R | |
| SCHEMBL12761344 | 0.70 | EPM2A (0.49) | EPM2APTPRCPTPN6CDC14APTPN22 | |
| SCHEMBL24065682 | 0.69 | ALDH1A1 (0.41) | ALDH1A1CYP19A1NPC1RAB9AAIMP2 | |
| SCHEMBL18910392 | 0.69 | ALDH1A1 (0.41) | ALDH1A1CYP19A1NPC1RAB9AAIMP2 | |
| SCHEMBL23024716 | 0.68 | CYP19A1 (0.46) | ALDH1A1CYP19A1NPC1RAB9AAIMP2 | |
| SCHEMBL25815539 | 0.67 | CYP19A1 (0.34) | ALDH1A1CYP19A1NPC1RAB9ALTB4R | |
| SCHEMBL22134628 | 0.66 | CYP19A1 (0.44) | ALDH1A1CYP19A1NPC1RAB9AAIMP2 | |
| SCHEMBL24904423 | 0.66 | TRPV1 (0.43) | ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647678-B2 | Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-12 | — | — | US | disclosed |
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | HSF1, HSP90AB1, HSP90AB2P | EPM2A 3218/4885PTPRC 3078/4885PTPN6 3458/4885 |
| US-10647678-B2 | Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity | HSF1, HSP90AB1, HSP90AB2P | EPM2A 3218/4885PTPRC 3078/4885PTPN6 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.